Insider Selling: Charles River Laboratories International (NYSE:CRL) EVP Sells $1,038,657.24 in Stock

Charles River Laboratories International, Inc. (NYSE:CRL) EVP Shannon Parisotto sold 3,714 shares of the firm’s stock in a transaction on Tuesday, August 11th. The stock was sold at an average price of $279.66, for a total value of $1,038,657.24. Following the completion of the transaction, the executive vice president directly owned 4,807 shares of the company’s stock, valued at approximately $1,344,325.62. This trade represents a 43.59% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Charles River Laboratories International Stock Performance

Charles River Laboratories International stock traded down $2.59 on Thursday, hitting $281.78. The company’s stock had a trading volume of 1,054,824 shares, compared to its average volume of 929,021. The firm has a market cap of $13.45 billion, a P/E ratio of -58.10, a price-to-earnings-growth ratio of 2.92 and a beta of 1.38. The company has a quick ratio of 1.04, a current ratio of 1.35 and a debt-to-equity ratio of 0.92. The company has a fifty day moving average price of $220.98 and a 200-day moving average price of $190.27. Charles River Laboratories International, Inc. has a one year low of $144.26 and a one year high of $288.02.

Charles River Laboratories International (NYSE:CRL) last released its quarterly earnings data on Wednesday, August 5th. The medical research company reported $3.02 EPS for the quarter, topping analysts’ consensus estimates of $2.77 by $0.25. Charles River Laboratories International had a negative net margin of 5.96% and a positive return on equity of 15.75%. The company had revenue of $1 billion during the quarter, compared to the consensus estimate of $980.53 million. During the same period last year, the firm earned $3.12 EPS. The firm’s revenue for the quarter was down 2.7% compared to the same quarter last year. Charles River Laboratories International has set its FY 2026 guidance at 11.150-11.450 EPS. On average, equities analysts anticipate that Charles River Laboratories International, Inc. will post 11.35 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of research analysts have commented on the stock. Weiss Ratings upgraded shares of Charles River Laboratories International from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Wednesday, July 1st. BNP Paribas Exane set a $250.00 target price on Charles River Laboratories International in a report on Wednesday, July 1st. Piper Sandler set a $300.00 target price on Charles River Laboratories International in a research report on Monday. Barclays reaffirmed an “overweight” rating and issued a $300.00 price target on shares of Charles River Laboratories International in a research note on Wednesday, August 5th. Finally, Citigroup reiterated a “buy” rating on shares of Charles River Laboratories International in a research report on Wednesday, July 8th. Twelve analysts have rated the stock with a Buy rating, three have given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $255.65.

Hedge Funds Weigh In On Charles River Laboratories International

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Madison Asset Management LLC bought a new stake in Charles River Laboratories International during the second quarter worth about $3,805,000. Great Lakes Advisors LLC bought a new position in shares of Charles River Laboratories International in the second quarter valued at approximately $459,000. Trust Asset Management LLC acquired a new position in shares of Charles River Laboratories International in the 2nd quarter worth approximately $129,000. Handelsbanken Fonder AB boosted its holdings in shares of Charles River Laboratories International by 36.9% in the 2nd quarter. Handelsbanken Fonder AB now owns 19,306 shares of the medical research company’s stock worth $4,378,000 after acquiring an additional 5,200 shares in the last quarter. Finally, Czech National Bank grew its position in Charles River Laboratories International by 2.3% during the 2nd quarter. Czech National Bank now owns 13,710 shares of the medical research company’s stock worth $3,109,000 after acquiring an additional 307 shares during the last quarter. 98.91% of the stock is currently owned by institutional investors and hedge funds.

About Charles River Laboratories International

Charles River Laboratories International, Inc is a leading provider of research models and preclinical and clinical support services for the pharmaceutical, biotechnology and medical device industries. The company’s core offerings include discovery, safety assessment, toxicology, and pathology services, as well as supply of laboratory animals and related diagnostics. Services extend across in vivo and in vitro testing, biologics testing, and support for advanced therapies, helping clients accelerate drug development from early discovery through regulatory submission.

Founded in 1947 in Wilmington, Massachusetts, Charles River has grown through strategic investments and acquisitions to establish a broad portfolio of capabilities.